Preparation and evaluation of carborane analogues of tamoxifen

Journal of Medicinal Chemistry

Volumn 53, Issue 22, 2010, Pages 8012-8020

  Beer, Michael L ^a   Lemon, Jennifer ^a   Valliant, John F ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1,2 DICARBA CLOSO DODECABORANE 1 YL) 1 (4 PHENOL) 2 PHENYLBUT 1 ENE; 4 HYDROXYTAMOXIFEN; CARBORANE DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR; IDOXIFENE; RALOXIFENE; TAMOXIFEN; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; ISOMERIZATION; STEREOCHEMISTRY; X RAY CRYSTALLOGRAPHY;

ADENOCARCINOMA; BORON COMPOUNDS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; FEMALE; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN;

EID: 78649506394     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100758j     Document Type: Article

References (39)

1. Jordan, V. C. Tamoxifen: a most unlikely pioneering medicine Nat. Drug Rev. 2003, 2, 205-213
2. Fisher, B.; Costantino, J. P.; Wickerham, D. L.; Redmond, C. K.; Kavanah, M.; Cronin, W. M.; Vogel, V.; Robidoux, A.; Dimitrov, N.; Atkins, J.; Daly, M.; Wieand, S.; Tan-Chiu, E.; Ford, L.; Wolmark, N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer Inst. 1998, 90 (18) 1371-1388
3. Gelber, R. D.; Cole, B. F.; Goldhirch, A.; Rose, C.; Fisher, B.; Osborne, C. K.; Boccardo, F.; Gray, R.; Gordon, N. H.; Bengtsson, N.; Sevelda, P. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality adjusted Lancet 1996, 347, 1066-1071
4. Bland, A. E.; Calingaert, B.; Secord, A. A.; Lee, P. S.; Valea, F. A.; Berchuck, A.; Soper, J. T.; Havrilesky, L. Relationship between tamoxifen use and high risk endometrial cancer histologic types Gynecol. Oncol. 2009, 112, 150-154
5. Yuvaraj, S.; Premkumar, V. G.; Shanthi, P.; Vijayasarathy, K.; Gangadaran, S. G. D.; Sachdanandam, P. Effect of coenzyme Q10, riboflavin and niacin on tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles Breast Cancer Res. Treat. 2009, 114, 377-384
6. Hoogendoorn, W. E.; Hollema, H.; van Boven, H. H.; Bergman, E.; de Leeuw-Mantel, G.; Platteel, I.; Fles, R.; Nederlof, P. M.; Mourits, M. J. E.; van Leeuwen, F. E.; Comprehensive Cancer Centers TAMARISK-Group. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer Breast Cancer Res. Treat. 2008, 112, 99-108
7. Dobrydneva, Y.; Weatherman, R. V.; Trebley, J. P.; Morrell, M. M.; Fitzgerald, M. C.; Fichandler, C. E.; Chatterjie, N.; Blackmore, P. F. Tamoxifen stimulates calcium entry into human platelets J. Cardiovasc. Pharmacol. 2007, 50, 380-390
8. Draper, M. W.; Flowers, D. E.; Neild, J. A.; Huster, W. J.; Zerbe, R. L. Antiestrogenic properties of raloxifene Pharmacology 1995, 50, 209-17
9. Pace, P.; Jarman, M.; Phillips, D.; Hewer, A.; Bliss, J.; Coombes, R. C. Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts Br. J. Cancer 1997, 76, 700-704
10. Borgna, J. L.; Rochefort, H. In vivo occupation of estrogen receptors by hydroxylated metabolites of tamoxifen Compt. Rend. 1979, 289, 1141-4
11. Wakeling, A. E.; Seater, S. R. Cancer Treat. Rep. 1980, 64, 741-744
12. Jordan, V. C. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance Breast Cancer Res. Treat. 1982, 2, 123-138
13. Endo, Y.; Iijima, T.; Yamakoshi, Y.; Kubo, A.; Itai, A. Structure-activity study of estrogenic agonists bearing dicarba-closo- dodecaborane. Effect of geometry and separation distance of hydroxyl groups at the ends of molecules Bioorg. Med. Chem. Lett. 1999, 9, 3313-3318
14. Endo, Y.; Iijima, T.; Yamakoshi, Y.; Yamaguchi, M.; Fukasawa, H.; Shudo, K. Potent estrogenic agonists bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore J. Med. Chem. 1999, 42, 1501-1504 (Pubitemid 29226721)
15. Endo, Y.; Iijima, Y.; Yamakoshi, Y.; Fukasawa, H.; Miyaura, C.; Inada, M.; Kubo, A.; Itai, A. Potent estrogen agonists based on carborane as a hydrophobic skeletal structure. A new medicinal application of boron clusters Chem. Biol. 2001, 8, 341-355
16. Endo, Y.; Yoshimi, T.; Miyaura, C. Boron clusters for medicinal drug design: selective estrogen receptor modulators bearing carborane Pure Appl. Chem. 2003, 75, 1197-1205
17. Tolpin, E. I.; Wong, H. S.; Lipscomb, W. K. Binding studies of boron hydride derivatives to proteins for neutron capture therapy J. Med. Chem. 1974, 17, 792-796
18. Kim, Y. S.; Kane, R. R.; Beno, C. L.; Romano, S.; Mendez, G.; Hawthorne, M. F. Synthesis of new building blocks for boron-rich oligomers in boron neutron capture therapy (BNCT). II. Monomers derived from 2,2-disubstituted-1,3-diols Tetrahedron Lett. 1995, 36, 5147-5150
19. Meo, C. D.; Panza, L.; Campo, F.; Capitani, D.; Mannina, L.; Banzato, A.; Rondina, M.; Rosato, A.; Crescenzi, V. Novel types of carborane-carrier hyaluronan derivatives via click chemistry Macromol. Biosci. 2008, 8, 670-681
20. Wong, H. S.; Tolpin, E. I.; Lipscomb, W. N. Boron hydride derivatives for neutron capture therapy. Antibody approach J. Med. Chem. 1974, 17, 785-791
21. Valliant, J. F.; Guenther, K. J.; King, A. S.; Morel, P.; Schaffer, P.; Sogbein, O. O.; Stephenson, K. A. The medicinal chemistry of carboranes Coord. Chem. Rev. 2002, 232, 173-230
22. Endo, Y.; Yoshimi, T.; Miyaura, C. Boron clusters for medicinal drug design: selective estrogen receptor modulators bearing carborane Pure Appl. Chem. 2003, 75, 1197-1205
23. Causey, P. W.; Besanger, T. R.; Valliant, J. F. Synthesis and screening of mono- and di-aryl technetium and rhenium metallocarboranes. A new class of probes for the estrogen receptor J. Med. Chem. 2008, 51, 2833-2844
24. Smyth, T. P.; Corby, B. W. Toward a clean alternative to Friedel-Crafts acylation: in situ formation, observation, and reaction of an acyl bis(trifluoroacetyl)phosphate and related structures J. Org. Chem. 1998, 63, 8946-8951
25. Kursari, U.; Li, Y.; Bradley, M. G.; Sneddon, L. G. Polyborane reactions in ionic liquids: new efficient routes to functionalized decaborane and o -carborane clusters J. Am. Chem. Soc. 2004, 126, 8662-8663
26. Hegstrom, R. A.; Newton, M. D.; Potenza, J. A.; Lipscomb, W. N. Chemical shifts of boron-11 in icosahedral carboranes J. Am. Chem. Soc. 1966, 88, 5340-5342
27. Rochefort, H.; Glondu, M.; Sahla, M. E.; Platet, N.; Garcia, M. How to target estrogen receptor-negative breast cancer? Endocr.-Relat. Cancer 2003, 10, 261-266
28. Weeks, C. M.; Griffin, J. F.; Duax, W. L. Am. Crystallogr. Assoc., Ser. 2 1977, 5, 69
29. Dickson, R. B.; Bates, S. E.; McManaway, M. E.; Lippman, M. E. Characterization of estrogen responsive transforming activity in human breast cancer cell lines Cancer Res. 1986, 46, 1707-1713
30. Endo, Y.; Yamamoto, K.; Kagechika, H. Utility of boron clusters for drug design. Relation between estrogen receptor binding affinity and hydrophobicity of phenols bearing various types of carboranyl groups Bioorg. Med. Chem. Lett. 2003, 13, 4089-4092
31. Zheng, A.; Kallio, A.; Harkonen, P. Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen Endocrine 2007, 148, 2764-2777
32. Zhang, W.; Couldwell, W. T.; Song, H.; Takano, T.; Lin, J. H. C.; Nedergaard, M. Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells Cancer Res. 2000, 60, 5395-5400
33. Ferlini, C.; Scambia, M.; Marone, M.; Distefano, M.; Gaggini, C.; Ferrandina, G.; Fattorossi, A.; Isola, G.; Benedetti Panici, P.; Mancuso, S. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines Br. J. Cancer 1999, 79, 257-263
34. Taylor, I. W.; Hodson, P. J.; Green, M. D.; Sutherland, R. L. Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells Cancer Res. 1983, 43, 4007-4010
35. Lehenkari, P.; Parikka, V.; Rautiala, T. J.; Weckstrom, M.; Dahllund, J.; Harkonen, P. L.; Vaananen, H. K. The effects of tamoxifen and toremifene on bone cells involve changes in plasma membrane ion conductance J. Bone Miner. Res. 2003, 18, 473-481
36. SMART: Area-Detector Software; Siemens Industrial Automation, Inc.: Madison, WI, 1993.
37. SAINT: Area-Detector Integration; Siemens Industrial Automation, Inc.: Madison, WI, 1995.
38. SADABS: Area-Detector Absorption; Siemens Industrial Automation, Inc.: Madison, WI, 1996.
39. Sheldrick, G. M. SHELXTL [Includes SHELXS97, SHELXL97, CIFTAB ] Programs for Crystal Structure Analysis; Institüt für Anorganische Chemie der Universität: Tammanstrasse 4, D-3400 Göttingen, Germany, 1998.